Clipping of news on Brazilian Culture, Law and Citizenship
07/16/2013
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Alana Gandra
Agency reporter Brazil
Rio de Janeiro - With non-reimbursable funds from the National Bank for Economic and Social Development (BNDES) of R $ 15.2 million, from the BNDES Technological Fund (Funtec), Instituto Butantan will follow up studies that seek to develop Biotechnology a medicament for the treatment of cancer.
As reported by the bank, through its spokesperson, the product is innovative in the world and is based on studies from the genetic tick Amblyoma cajannense, which detected the presence of a protein in the saliva of the parasite that has anticoagulant action, with anticancer potential.
The study coordinator at the Butantan Institute, Dr. Ana Marisa Chudzinski-Tavassi, said by e-mail, AGENCY Brazil that all basic research for the discovery of the molecule, understanding the mechanism of action and obtaining of the same molecule in the laboratory scale, since was done at the Laboratory of Biochemistry and Biophysics Institute.
The operation received funding from the Foundation for Research Support of the State of São Paulo (FAPESP). The organization also contributed to the steps that result in the execution of tests, as well as for the infrastructure deployment.
BNDES funds will allow the molecule is obtained through scalable protocols. Ana Marisa pointed out that these protocols "will allow both the development of all safety pharmacology tests, required by regulatory bodies such as the development of technology and training of personnel for transfer of the case to the company partner in this project (União Química) that produce the medicine ". It is, according to the researcher, funding for steps "very important and critical to the development of a molecule, characterized as radical innovation."
The experiments conducted so far resulted in the development of the molecule in recombinant form, said lead researcher. "We know its mechanism of action in vitro [glass] and in vivo, that is, in small animals, we know the molecular target and even understand that it is a molecule selective for tumor cells. Studies so far have shown very low toxicity. " He added that the step now underway aims to get stuff for scalable protocols to complement the tests of safety pharmacology and technology transfer.
Asked about the types of cancers that can be treated with medication, Ana Marisa reported that the first experiments in mice showed that there was regression of tumor cells and tumor-type melanoma, among which include tumors of the skin, kidneys, pancreas and breast . Noted, however, that only after the results of toxicology tests, which will determine the safety of treatment for humans is that it could provide the treatment.
The National Union Pharmaceutical Chemistry, Institute Butantan partner in the project, should develop phases of industrial production and clinical phases, in case of success of the research. The Union is cotitular Chemistry and holds the patent licensing for marketing, said the company, through its press office. Another partner is the Institute for Technological Research of São Paulo (IPT), which participate in the production protocol.
Ana Marisa also said that the molecule has already granted patent in several countries, including the United States, Japan, Australia and China, plus the block of the European Union.
Source: Agency Brazil
Our news are taken in full from our partner sites. For this reason, we can not change the contents of the same even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.